JP2009506978A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009506978A5 JP2009506978A5 JP2008508028A JP2008508028A JP2009506978A5 JP 2009506978 A5 JP2009506978 A5 JP 2009506978A5 JP 2008508028 A JP2008508028 A JP 2008508028A JP 2008508028 A JP2008508028 A JP 2008508028A JP 2009506978 A5 JP2009506978 A5 JP 2009506978A5
- Authority
- JP
- Japan
- Prior art keywords
- insulin
- phase
- component
- pharmaceutical
- linkage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 183
- KWIUHFFTVRNATP-UHFFFAOYSA-N Trimethylglycine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims 94
- 102000004877 Insulin Human genes 0.000 claims 88
- 108090001061 Insulin Proteins 0.000 claims 88
- 239000000203 mixture Substances 0.000 claims 81
- 239000008194 pharmaceutical composition Substances 0.000 claims 43
- 229960003237 betaine Drugs 0.000 claims 41
- 239000004026 insulin derivative Substances 0.000 claims 31
- 108010026951 Short-Acting Insulin Proteins 0.000 claims 18
- 239000004615 ingredient Substances 0.000 claims 11
- 108010092217 Long-Acting Insulin Proteins 0.000 claims 9
- 102000016261 Long-Acting Insulin Human genes 0.000 claims 9
- 230000003111 delayed Effects 0.000 claims 8
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N diguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims 8
- 239000011324 bead Substances 0.000 claims 6
- 239000011248 coating agent Substances 0.000 claims 6
- 238000000576 coating method Methods 0.000 claims 6
- 239000002245 particle Substances 0.000 claims 6
- 239000002552 dosage form Substances 0.000 claims 5
- 210000004369 Blood Anatomy 0.000 claims 4
- 239000008280 blood Substances 0.000 claims 4
- 150000002148 esters Chemical class 0.000 claims 4
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000011780 sodium chloride Substances 0.000 claims 4
- 102000014961 Protein Precursors Human genes 0.000 claims 3
- 108010078762 Protein Precursors Proteins 0.000 claims 3
- 229920003176 water-insoluble polymer Polymers 0.000 claims 3
- 230000036912 Bioavailability Effects 0.000 claims 2
- 230000035514 bioavailability Effects 0.000 claims 2
- 238000002288 cocrystallisation Methods 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 230000000875 corresponding Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000002797 proteolythic Effects 0.000 claims 2
- 230000002459 sustained Effects 0.000 claims 2
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- WNRQPCUGRUFHED-DETKDSODSA-N Humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 claims 1
- 108010065920 Insulin Lispro Proteins 0.000 claims 1
- 229960002068 Insulin Lispro Drugs 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 208000001072 Type 2 Diabetes Mellitus Diseases 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- 230000000717 retained Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Claims (91)
成分または相または形態のAであり、1種またはそれよりも多くの短時間作用型のインスリンを備え、および一般式(CH3)3N+−(CH2)n−COO−で表されnが1から5の整数であるベタインが備わらないもの、および、
成分または相または形態のBであり、
a 1種またはそれよりも多くの短時間作用型インスリン、および
b 一般式(CH3)3N+−(CH2)n−COO−で表されnが1から5の整数であるベタイン、それらの薬学的に許容される塩類、それらのエステル類、それらの前駆体、またはそれらの混合物を備えるもの
が組み合わせられた薬学的な組成物。 A pharmaceutical composition comprising:
A component or phase or form of A, comprising one or more short-acting insulins and represented by the general formula (CH 3 ) 3 N + — (CH 2 ) n —COO — Without betaine where is an integer from 1 to 5, and
Component or phase or form B,
a one or more short-acting insulins, and b betaines represented by the general formula (CH 3 ) 3 N + — (CH 2 ) n —COO − , where n is an integer from 1 to 5, A pharmaceutical composition comprising a combination of pharmaceutically acceptable salts, esters thereof, precursors thereof, or mixtures thereof.
成分または相または形態のAであり、1種またはそれよりも多くの短時間作用型インスリンを備えるもので、前記成分または相または形態のAは有利には実質的にベタインを備えないものであり、および
成分または相または形態のBであり、
a 短時間作用型インスリン、中間作用型インスリン、長時間作用型インスリン、およびそれらの混合物からなる群より選ばれる1種またはそれよりも多くの化合物、および
b 一般式(CH3)3N+−(CH2)n−COO−で表されnが1から5の整数、なるべくなら1であるベタイン、それらの薬学的に許容される塩類、それらのエステル類、それらの前駆体、またはそれらの混合物
の混合物を備えるもの
が組み合わせられた薬学的な組成物。 A pharmaceutical composition comprising:
An ingredient or phase or form A, comprising one or more short-acting insulins, said ingredient or phase or form A being advantageously substantially free of betaine And B of component or phase or form,
a one or more compounds selected from the group consisting of short-acting insulin, intermediate-acting insulin, long-acting insulin, and mixtures thereof, and b general formula (CH 3 ) 3 N + − Betaine represented by (CH 2 ) n —COO — , wherein n is an integer of 1 to 5, preferably 1, pharmaceutically acceptable salts thereof, esters thereof, precursors thereof, or mixtures thereof A pharmaceutical composition combined with a mixture comprising:
成分または相または形態のAであり、1種またはそれよりも多くの短時間型インスリン、および一般式(CH3)3N+−(CH2)n−COO−で表されnが1から5の整数であるベタインを備えるもの、および、
成分または相または形態のBであり、
a 1種またはそれよりも多くの短時間作用型インスリン、および
b 一般式(CH3)3N+−(CH2)n−COO−で表されnが1から5の整数であるベタイン、それらの薬学的に許容される塩類、それらのエステル類、それらの前駆体、またはそれらの混合物を備え、成分または相または形態のAのインスリンは成分または相または形態のBのインスリンと異なっているところのもの
が組み合わせられた、薬学的な組成物。 A pharmaceutical composition comprising:
A component or phase or in the form of A, 1 kind or more of a short-acting insulin than, and the general formula (CH 3) 3 N + - (CH 2) n -COO - from represented n is 1 to 5 With betaine that is an integer of
Component or phase or form B,
a one or more short-acting insulins, and b betaines represented by the general formula (CH 3 ) 3 N + — (CH 2 ) n —COO − , where n is an integer from 1 to 5, A pharmaceutically acceptable salt, ester thereof, precursor thereof, or a mixture thereof, wherein the component or phase or form A insulin is different from the component or phase or form B insulin A pharmaceutical composition comprising a combination of the above.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BEPCT/BE2005/000061 | 2005-04-27 | ||
PCT/BE2006/000040 WO2006113978A2 (en) | 2005-04-27 | 2006-04-27 | Insulins combinations |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009506978A JP2009506978A (en) | 2009-02-19 |
JP2009506978A5 true JP2009506978A5 (en) | 2009-06-18 |
Family
ID=37215100
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008508028A Pending JP2009506978A (en) | 2005-04-27 | 2006-04-27 | Combination of insulins |
Country Status (10)
Country | Link |
---|---|
US (1) | US7786077B2 (en) |
EP (1) | EP1885392B1 (en) |
JP (1) | JP2009506978A (en) |
CN (1) | CN101180073A (en) |
AT (1) | ATE540690T1 (en) |
BR (1) | BRPI0610249A2 (en) |
CA (1) | CA2650556A1 (en) |
MX (1) | MX2007013486A (en) |
RU (1) | RU2007143510A (en) |
WO (1) | WO2006113978A2 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE1015608A6 (en) * | 2003-07-15 | 2005-06-07 | Messadek Jallal | TREATMENT arteritis. |
EP1615632B1 (en) * | 2003-04-17 | 2006-12-06 | Jallal Messadek | Floating oral formulations for controlled release of betaine |
WO2009065193A1 (en) * | 2007-11-21 | 2009-05-28 | Jallal Messadek | Treatment of aspirin resistance with betaine and/or betaine enriched molasses |
BRPI0822909B8 (en) * | 2008-06-26 | 2021-05-25 | Laboratorios Silanes S A De C V | metformin glycinate salt for blood glucose control |
WO2011094632A1 (en) * | 2010-01-29 | 2011-08-04 | The Uab Research Foundation | Method for administration of insulin and pharmaceutical composition thereof |
RU2483749C2 (en) * | 2011-04-15 | 2013-06-10 | Леонид Леонидович Клопотенко | Pharmaceutical composition containing insulin and liposomes for topical application in form of biofilm |
RU2483748C2 (en) * | 2011-04-15 | 2013-06-10 | Леонид Леонидович Клопотенко | Pharmaceutical composition containing insulin and liposomes for topical application in form of plaster |
US10143754B2 (en) * | 2011-08-07 | 2018-12-04 | Transgene Biotek Limited | Method for peroral delivery of insulin and its analogues for therapeutic usage |
US9897565B1 (en) | 2012-09-11 | 2018-02-20 | Aseko, Inc. | System and method for optimizing insulin dosages for diabetic subjects |
US9171343B1 (en) | 2012-09-11 | 2015-10-27 | Aseko, Inc. | Means and method for improved glycemic control for diabetic patients |
US20150065423A1 (en) * | 2013-08-30 | 2015-03-05 | Perosphere, Inc. | Rapid acting injectable formulations |
US9486580B2 (en) | 2014-01-31 | 2016-11-08 | Aseko, Inc. | Insulin management |
US9233204B2 (en) | 2014-01-31 | 2016-01-12 | Aseko, Inc. | Insulin management |
US11081226B2 (en) | 2014-10-27 | 2021-08-03 | Aseko, Inc. | Method and controller for administering recommended insulin dosages to a patient |
AU2015339576B2 (en) | 2014-10-27 | 2020-02-06 | Aseko, Inc. | Subcutaneous outpatient management |
WO2017031440A1 (en) | 2015-08-20 | 2017-02-23 | Aseko, Inc. | Diabetes management therapy advisor |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2590M (en) | 1963-03-12 | 1964-06-15 | Albert Beaufour | New anti-neuralgic associations with improved tolerance. |
US3577534A (en) | 1968-06-20 | 1971-05-04 | Canada Packers Ltd | Stable orally active heparinoid complexes |
FR2119889A1 (en) | 1970-12-31 | 1972-08-11 | Vegetti Tiberio | Deoxyribonucleic acid compsns - for treating degenerating mesenchyma,parenchyma or arteriosclerosis |
GB1509979A (en) | 1975-11-28 | 1978-05-10 | Fisons Ltd | Pharmaceutical compositions containing aspirin or indomethacin |
FR2403799A2 (en) | 1977-09-27 | 1979-04-20 | Union Pharma Scient Appl | Prepn. of injectable aspirin solns. - by mixing aspirin with arginine or lysine, glutamic acid, betaine and water |
US4605548A (en) | 1983-05-31 | 1986-08-12 | Nitto Electric Industrial Co., Ltd. | Drug administration material |
GB8325627D0 (en) | 1983-09-24 | 1983-10-26 | Scras | Therapeutic compositions |
PL149493B1 (en) | 1985-04-12 | 1990-02-28 | Method of obtaining a tablet capable to buoy over surface of gastric juice | |
AU607172B2 (en) | 1986-12-22 | 1991-02-28 | Cygnus, Inc. | Diffusion matrix for transdermal drug administration |
HU210122B (en) | 1988-03-23 | 1995-02-28 | Biorex Kutato Fejlesztoe Kft | Process for production of composition against thromboembolytic conditions of circulating system and heart |
US4902718A (en) | 1988-04-08 | 1990-02-20 | Bayless Robert K | Calcium homeostasis compositions and methods for controlling calcium metabolism |
MC2041A1 (en) | 1988-06-24 | 1990-05-30 | Johannes Cornelius Str Andries | ANTI-ATHEROGENIC AGENTS |
IT1226386B (en) | 1988-07-08 | 1991-01-15 | Chiesi Farma Spa | MORNIFLUMATO AND ANALOGUE PREPARATION PROCEDURE. |
US4968719A (en) | 1989-04-03 | 1990-11-06 | Sigma Tau, Industrie Farmaceutiche Riunite Spa | Method for treating vascular disease |
US5405614A (en) | 1992-04-08 | 1995-04-11 | International Medical Associates, Inc. | Electronic transdermal drug delivery system |
US5342621A (en) | 1992-09-15 | 1994-08-30 | Advanced Cardiovascular Systems, Inc. | Antithrombogenic surface |
US5876780A (en) | 1993-04-29 | 1999-03-02 | Cultor, Ltd. | Compositions for treating coccidiosis |
US5716941A (en) | 1993-07-07 | 1998-02-10 | Biogenesys | Use of methyl donor compounds to treat neurological dysfunction associated with immune defects |
US5814599A (en) | 1995-08-04 | 1998-09-29 | Massachusetts Insitiute Of Technology | Transdermal delivery of encapsulated drugs |
AU1265295A (en) | 1993-12-10 | 1995-06-27 | Sami A. Hashim | Reducing likelihood of vascular disorders in susceptible patients |
US6355166B1 (en) | 1994-08-25 | 2002-03-12 | The University Of Iowa Research Foundation | Magnetically enhanced composite materials and methods for making and using the same |
JP3234113B2 (en) * | 1994-11-11 | 2001-12-04 | 日本甜菜製糖株式会社 | Blood glucose elevation inhibitors and uses |
US5961999A (en) | 1995-06-08 | 1999-10-05 | Wella Aktiengesellschaft | Method of skin care using a skin care preparation containing a betaine ester and an α-hydroxy acid |
JP3119430B2 (en) | 1995-07-25 | 2000-12-18 | 大鵬薬品工業株式会社 | Hydroxyl radical scavenger |
US6162926A (en) | 1995-07-31 | 2000-12-19 | Sphere Biosystems, Inc. | Multi-substituted fullerenes and methods for their preparation and characterization |
LV11727B (en) | 1995-08-21 | 1997-08-20 | Kalvins Ivars | Pharmaceutical composition |
US7045585B2 (en) | 1995-11-30 | 2006-05-16 | Hamilton Civic Hospital Research Development Inc. | Methods of coating a device using anti-thrombin heparin |
WO1997027829A1 (en) | 1996-01-31 | 1997-08-07 | The Trustees Of The University Of Pennsylvania | Remote control drug delivery device |
SE9601395D0 (en) | 1996-04-12 | 1996-04-12 | Dieter Haeussinger | New therapeutic treatment 1 |
SE9601396D0 (en) | 1996-04-12 | 1996-04-12 | Dieter Haeussinger | New therapeutic treatment 2 |
US5880098A (en) | 1996-04-12 | 1999-03-09 | Pharmacia & Upjohn Aktiebolag | Therapeutic treatment |
IL119029A0 (en) * | 1996-08-07 | 1996-11-14 | Yeda Res & Dev | Long-acting drugs and pharamaceutical compositions comprising them |
US6008221A (en) | 1996-11-06 | 1999-12-28 | Bristol-Myers Squibb Company | Method for treating Alzheimer's disease with folic acid |
US6495579B1 (en) | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
JP3174013B2 (en) | 1997-05-15 | 2001-06-11 | コビシ電機株式会社 | Sealed sensor |
US6258859B1 (en) | 1997-06-10 | 2001-07-10 | Rhodia, Inc. | Viscoelastic surfactant fluids and related methods of use |
EP1061908A4 (en) | 1998-03-13 | 2007-01-24 | Merck & Co Inc | Combination therapy and composition for acute coronary ischemic syndrome and related conditions |
US6235311B1 (en) | 1998-03-18 | 2001-05-22 | Bristol-Myers Squibb Company | Pharmaceutical composition containing a combination of a statin and aspirin and method |
US6287765B1 (en) | 1998-05-20 | 2001-09-11 | Molecular Machines, Inc. | Methods for detecting and identifying single molecules |
WO2000025764A2 (en) | 1998-10-30 | 2000-05-11 | Merck Patent Gmbh | Compositions for the treatment and prevention of cardiovascular diseases |
JP2000143486A (en) | 1998-11-12 | 2000-05-23 | Lion Corp | Skin preparation for external use |
US7608640B2 (en) | 1999-03-02 | 2009-10-27 | Jallal Messadek | Glycine betaine and its use |
BE1012495A3 (en) | 1999-03-02 | 2000-11-07 | Messadek Jallal | Glycine betaine-for its use antithrombotic. |
BE1012546A6 (en) | 1999-03-10 | 2000-12-05 | Messadek Jallal | Betaine and its derivatives for their antithrombotic use |
DE19910682B4 (en) | 1999-03-10 | 2004-09-02 | Dierkes, Jutta, Dr. | Use of a combination preparation for the therapy of fibrate-induced hyperhomocysteinemia |
BE1012712A6 (en) | 1999-06-10 | 2001-02-06 | Messadek Jallal | Antithrombotic peptides |
DE10004651A1 (en) | 2000-02-03 | 2001-08-16 | Jutta Dierkes | Combination of antihypertensive agents with drugs that reduce homocysteine levels |
JP2004501190A (en) | 2000-06-23 | 2004-01-15 | テバ ファーマシューティカル インダストリーズ リミティド | Rapidly expanding compositions for gastric retention and controlled release of therapeutic agents and dosage forms containing the compositions |
US6881420B2 (en) | 2000-06-23 | 2005-04-19 | Teva Pharmaceutical Industries Ltd. | Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation |
US6476006B2 (en) | 2000-06-23 | 2002-11-05 | Teva Pharmaceutical Industries, Ltd. | Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates |
FR2811227A1 (en) | 2000-07-07 | 2002-01-11 | Philippe Maincent | PARTICULATE VECTORS FOR IMPROVING ORAL ABSORPTION OF ACTIVE PRINCIPLES |
CA2430037A1 (en) | 2000-11-20 | 2002-05-30 | Michael S. South | Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade |
JP2004515508A (en) * | 2000-12-16 | 2004-05-27 | アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | COMPOUND HEALTH PROMOTING COMPOSITION |
FI114538B (en) | 2001-01-12 | 2004-11-15 | Finnfeeds Finland Ltd | Use of glycine betaine for the preparation of a blood pressure lowering product |
DK1408949T3 (en) | 2001-02-05 | 2008-04-28 | Jallal Messadek | Glycine betaine and its scope of the invention |
WO2002066002A2 (en) | 2001-02-14 | 2002-08-29 | Glaxo Wellcome S.A. | Pharmaceutical formulation |
US20040072750A1 (en) | 2001-05-03 | 2004-04-15 | David Phillips | Compounds and methods for the modulation of CD154 |
US20030054978A1 (en) | 2001-08-31 | 2003-03-20 | Babish John G. | Arginine compositions for coordinate modification of multiple cardiovascular risk factors |
US20060160896A1 (en) | 2002-02-04 | 2006-07-20 | Jallal Messadek | Therapeutic treatment |
BE1015608A6 (en) | 2003-07-15 | 2005-06-07 | Messadek Jallal | TREATMENT arteritis. |
CA2478700C (en) | 2002-03-11 | 2012-10-16 | Momenta Pharmaceuticals, Inc. | Analysis of sulfated polysaccharides |
US20040067986A1 (en) | 2002-10-04 | 2004-04-08 | Nathan Sassover | Neuro-degenerative inhibitor, neuro-endocrine modulator, and neuro-cerebral metabolism enhancer |
ES2364155T3 (en) | 2002-11-25 | 2011-08-25 | Jallal Messadek | COMPOSITIONS OF BETAINE AND ACETILSALICYL ACID. |
EP1615632B1 (en) | 2003-04-17 | 2006-12-06 | Jallal Messadek | Floating oral formulations for controlled release of betaine |
US7097968B2 (en) | 2003-07-10 | 2006-08-29 | General Atomics | Methods and compositions for assaying homocysteine |
US20060128657A1 (en) | 2003-08-04 | 2006-06-15 | Jallal Messadek | Selected betaines and their uses |
CA2575760A1 (en) | 2003-08-04 | 2005-02-10 | Jallal Messadek | Selected betaines and their uses |
EP1663174A1 (en) | 2003-08-05 | 2006-06-07 | Galephar M/F | Single unit pharmaceutical composition comprising a mixture of a fibrate and a homocysteine reducing agent |
WO2005065675A1 (en) | 2004-01-07 | 2005-07-21 | Premacs International Pty. Ltd. | Method of treatment |
BE1016128A6 (en) | 2004-07-22 | 2006-03-07 | Messadek Jallal | Combination therapy |
WO2006050581A2 (en) | 2004-11-10 | 2006-05-18 | Jallal Messadek | Betaine as agent against arthropod - or mosquito -borne diseases |
WO2006086856A1 (en) | 2005-02-15 | 2006-08-24 | Messadek, Jallal | Combination therapeutic compositions and method of use |
-
2006
- 2006-04-27 MX MX2007013486A patent/MX2007013486A/en active IP Right Grant
- 2006-04-27 JP JP2008508028A patent/JP2009506978A/en active Pending
- 2006-04-27 EP EP06741296A patent/EP1885392B1/en not_active Not-in-force
- 2006-04-27 BR BRPI0610249-2A patent/BRPI0610249A2/en not_active IP Right Cessation
- 2006-04-27 CN CNA2006800176286A patent/CN101180073A/en active Pending
- 2006-04-27 WO PCT/BE2006/000040 patent/WO2006113978A2/en active Application Filing
- 2006-04-27 CA CA002650556A patent/CA2650556A1/en not_active Abandoned
- 2006-04-27 AT AT06741296T patent/ATE540690T1/en active
- 2006-04-27 RU RU2007143510/15A patent/RU2007143510A/en not_active Application Discontinuation
-
2007
- 2007-10-29 US US11/927,172 patent/US7786077B2/en not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009506978A5 (en) | ||
RU2019100425A (en) | NEW DOSE AND PREPARATION FORM | |
HRP20170056T2 (en) | Low frequency glatiramer acetate therapy | |
US20080089861A1 (en) | Combination therapy for treatment of demyelinating conditions | |
JP2010518122A5 (en) | ||
DK2574167T3 (en) | LIQUID NOSE SPRAY CONTAINING low-dose naltrexone | |
JP2003292443A5 (en) | ||
JP2010523587A5 (en) | ||
JP2008520736A5 (en) | ||
JP2010525050A5 (en) | ||
RU2007143510A (en) | INSULIN COMPOSITIONS | |
WO2006121560A2 (en) | Methods and compositions for treatment of cns disorders | |
JP2011500851A5 (en) | ||
JP2011511789A5 (en) | ||
JP2014524480A5 (en) | ||
AU2017345720B2 (en) | Terlipressin compositions and their methods of use | |
Kim et al. | Hallmarks of treatment aspects: Parkinson's disease throughout centuries including L-dopa | |
TW200306799A (en) | Combination of organic compounds | |
JP2018507243A5 (en) | ||
JP2017533211A5 (en) | ||
JP2016505050A5 (en) | ||
JP2020510043A5 (en) | ||
JP2017531044A5 (en) | ||
US20220265776A1 (en) | Combination | |
JP2016166231A (en) | Medicines for treatment of neuropathic diseases |